[Latest] Global Dry Eye Syndrome Treatment Market Size/Share Worth USD 12,281.4 Million by 2033 at a 7.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
11 déc. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Dry Eye Syndrome Treatment Market Size, Trends and Insights By Type (Evaporative...
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
27 oct. 2021 07h00 HE
|
Recro Pharma, Inc.
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN...
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
20 avr. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Expertise in Lipid Management with...
Otsuka Pharmaceutical Development & Commercialization, Inc. Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool
09 mai 2018 23h01 HE
|
Open Minds
Gettysburg, PA, May 09, 2018 (GLOBE NEWSWIRE) -- Nearly 3.4 million adults, or 1.1% of the U.S. population, are affected by schizophrenia.1,2 As a chronic, relapsing condition, those who have...
2017 OPEN MINDS Technology & Informatics Faculty List Announced; Includes Leaders From Over 30 Influential Health & Human Service Organizations
17 oct. 2017 07h30 HE
|
Open Minds
Gettysburg, PA, Oct. 17, 2017 (GLOBE NEWSWIRE) -- OPEN MINDS recently announced the faculty list for this year’s 2017 OPEN MINDS Technology & Informatics Institute taking place on November 7-8,...
Cutting Edge Information Analyzes the Bristol-Myers Squibb / Otsuka Pharma Profit-Sharing Strategy for 2010 and Beyond
16 avr. 2009 10h17 HE
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - April 16, 2009) - The recently announced deal
between Bristol-Myers Squibb and Otsuka over Abilify will go a long way
toward shoring up both companies'...